Daiichi Sankyo Company, Limited(DSKYF) News

Date	Title
Sep 7	DS-3939 Enters Clinical Development in Patients Across Several Types of Advanced Solid Cancers
Jul 3	Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients with Advanced Non Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial